Pharmaceutical Compound Overview
Lipvas 20 mg is a pharmaceutical-grade atorvastatin calcium formulation manufactured by Cipla Limited. Atorvastatin calcium is a synthetic lipophilic statin belonging to the HMG-CoA reductase inhibitor class, extensively researched for its cholesterol biosynthesis pathway modulation properties. This well-characterised pharmaceutical compound serves as a valuable reference standard in cardiovascular and metabolic research applications.
The compound exhibits potent inhibitory activity against 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. Research investigations have demonstrated atorvastatin’s pleiotropic effects beyond lipid modification, including endothelial function modulation and inflammatory pathway regulation. Each Lipvas tablet provides precisely 20mg of atorvastatin calcium equivalent to atorvastatin free acid, ensuring consistent analytical results across experimental protocols.
Laboratory Research Applications
Researchers at Stroid UK Shop frequently examine atorvastatin for its multifaceted cellular mechanisms in cardiovascular disease models. Studies investigate its role in cholesterol homeostasis, examining both direct enzymatic inhibition and downstream effects on cellular lipid metabolism. The compound’s well-documented pharmacokinetic profile makes it suitable for comparative analysis with other hypolipidemic agents in laboratory settings.
Molecular biology research utilises atorvastatin calcium to evaluate HMG-CoA reductase pathway modulation and its effects on mevalonate-dependent cellular processes. Investigators examine isoprenoid intermediate depletion effects on protein prenylation, particularly focusing on small GTPase function. The compound serves as a positive control in statin mechanism studies and provides researchers with a pharmaceutical-grade reference for lipid-lowering pathway investigations.
Comparative studies often evaluate atorvastatin alongside selective androgen receptor modulators and peptide compounds when investigating metabolic syndrome models. Researchers analyse potential synergistic effects between different compound classes in comprehensive metabolic research protocols.
Technical Specifications
| Parameter | Specification |
|---|---|
| Active Ingredient | Atorvastatin Calcium |
| Strength | 20 mg |
| Manufacturer | Cipla Limited |
| Formulation | Film-coated tablet |
| CAS Number | 134523-03-8 |
| Molecular Formula | C₆₆H₆₈CaF₂N₄O₁₀ |
| Molecular Weight | 1155.36 g/mol |
| Storage Conditions | Room temperature, dry |
Research Compliance Statement
Lipvas 20 mg is supplied exclusively for in-vitro laboratory research purposes and analytical reference applications. This pharmaceutical compound is not intended for human consumption, therapeutic use, or any clinical applications. Researchers must ensure appropriate institutional oversight and safety protocols when handling this material. All experimental work should comply with relevant laboratory safety guidelines and institutional review board requirements for research chemical handling.
